{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:06:16Z","timestamp":1789520776881,"version":"build-2803163510"},"reference-count":246,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["2025HXFH018"],"award-info":[{"award-number":["2025HXFH018"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2026NSFSCZY0134"],"award-info":[{"award-number":["2026NSFSCZY0134"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92574109"],"award-info":[{"award-number":["92574109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472774"],"award-info":[{"award-number":["82472774"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3403200"],"award-info":[{"award-number":["2023YFC3403200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbcan.2026.189692","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T06:18:57Z","timestamp":1787552337000},"page":"189692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-translational modifications in prostate cancer: coordinated oncogenic networks and clinical implications"],"prefix":"10.1016","volume":"1881","author":[{"given":"Huan","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanji","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiliang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2026.189692_bb0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate Cancer epidemiology and risk factors-a systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0010","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2026.189692_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbcan.2026.189692_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bbcan.2026.189692_bb0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.semcancer.2004.06.005","article-title":"The epigenetics of cancer etiology","volume":"14","author":"Feinberg","year":"2004","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189692_bb0035","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189692_bb0040","doi-asserted-by":"crossref","first-page":"D512","DOI":"10.1093\/nar\/gku1267","article-title":"PhosphoSitePlus, 2014: mutations, PTMs and recalibrations","volume":"43","author":"Hornbeck","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0045","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/nm.4378","article-title":"Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4","volume":"23","author":"Dai","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189692_bb0050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41580-021-00441-y","article-title":"Modulation of cellular processes by histone and non-histone protein acetylation","volume":"23","author":"Shvedunova","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0055","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/cancers14020346","article-title":"Lysine acetylation, cancer hallmarks and emerging onco-therapeutic opportunities","volume":"14","author":"Hu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189692_bb0060","doi-asserted-by":"crossref","first-page":"15969","DOI":"10.1073\/pnas.0604193103","article-title":"Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1","volume":"103","author":"Chen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189692_bb0065","doi-asserted-by":"crossref","first-page":"33141","DOI":"10.1074\/jbc.M111.252080","article-title":"Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5","volume":"286","author":"Hsu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2026.189692_bb0070","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.bbamcr.2017.11.011","article-title":"Selective inhibition reveals cyclin-dependent kinase 2 as another kinase that phosphorylates the androgen receptor at serine 81","volume":"1865","author":"Jorda","year":"2018","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0075","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/1878-0261.12968","article-title":"Phosphorylation of the androgen receptor at Ser81 is co-sustained by CDK1 and CDK9 and leads to AR-mediated transactivation in prostate cancer","volume":"15","author":"Gao","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0080","first-page":"3738","article-title":"Positive feedback loop mediated by protein phosphatase 1\u03b1 mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer","volume":"45","author":"Liu","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0085","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168649","article-title":"Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs","volume":"134","author":"Han","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189692_bb0090","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1038\/onc.2012.412","article-title":"Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer","volume":"32","author":"Ha","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189692_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114794","article-title":"Androgen receptor phosphorylated at Ser815: the expression and function in the prostate and tumor-derived cells","volume":"194","author":"Yokobori","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.canlet.2019.03.044","article-title":"Activation of PSGR with \u03b2-ionone suppresses prostate cancer progression by blocking androgen receptor nuclear translocation","volume":"453","author":"Xie","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189692_bb0105","first-page":"862125","article-title":"Androgen receptor signalling in prostate cancer: the functional consequences of acetylation","volume":"2011","author":"Lavery","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0110","doi-asserted-by":"crossref","first-page":"20853","DOI":"10.1074\/jbc.M000660200","article-title":"p300 and p300\/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation","volume":"275","author":"Fu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2026.189692_bb0115","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1128\/MCB.23.23.8563-8575.2003","article-title":"Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth","volume":"23","author":"Fu","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0120","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/pros.21088","article-title":"Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus","volume":"70","author":"Shiota","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.bbcan.2026.189692_bb0125","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1073\/pnas.1113356109","article-title":"Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis","volume":"109","author":"Wang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189692_bb0130","doi-asserted-by":"crossref","first-page":"71417","DOI":"10.18632\/oncotarget.12163","article-title":"Acetylation of androgen receptor by ARD1 promotes dissociation from HSP90 complex and prostate tumorigenesis","volume":"7","author":"DePaolo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189692_bb0135","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0140","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-18-2738","article-title":"AKT as a therapeutic target for cancer","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0145","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189692_bb0150","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-22-0264","article-title":"SETDB1 modulates degradation of phosphorylated RB and anticancer efficacy of CDK4\/6 inhibitors","volume":"83","author":"Huang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0155","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114168","article-title":"STAT3 signaling in prostate cancer progression and therapy resistance: an oncogenic pathway with diverse functions","volume":"158","author":"Sadrkhanloo","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189692_bb0165","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1172\/JCI86505","article-title":"MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression","volume":"126","author":"Dallavalle","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189692_bb0170","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1091\/mbc.e08-08-0792","article-title":"PCAF acetylates {beta}-catenin and improves its stability","volume":"20","author":"Ge","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bbcan.2026.189692_bb0175","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ncb1668","article-title":"Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation","volume":"10","author":"Metzger","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0180","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ccell.2017.05.003","article-title":"ACK1\/TNK2 regulates histone H4 Tyr88-phosphorylation and AR gene expression in castration-resistant prostate cancer","volume":"31","author":"Mahajan","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189692_bb0185","doi-asserted-by":"crossref","first-page":"6556","DOI":"10.1038\/s41388-020-01456-z","article-title":"Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer","volume":"39","author":"Wen","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189692_bb0190","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.7150\/thno.73223","article-title":"Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bbcan.2026.189692_bb0195","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","article-title":"Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer","volume":"578","author":"Faivre","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189692_bb0200","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189692_bb0205","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","article-title":"Understanding the complexity of p53 in a new era of tumor suppression","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189692_bb0210","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.4161\/cc.4.9.1966","article-title":"Blockage of NF-kappaB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells","volume":"4","author":"Zerbini","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2026.189692_bb0215","first-page":"353","article-title":"Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases","volume":"41","author":"Thakur","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0220","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ng.3419","article-title":"The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis","volume":"47","author":"Pomerantz","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2026.189692_bb0225","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1158\/1078-0432.CCR-21-3603","article-title":"Acetylated HOXB13 regulated super enhancer genes define therapeutic vulnerabilities of castration-resistant prostate cancer","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0230","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3390\/cancers16091622","article-title":"Amino terminal acetylation of HOXB13 regulates the DNA damage response in prostate cancer","volume":"16","author":"Nguyen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189692_bb0235","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/1541-7786.MCR-23-0086","article-title":"Hierarchical phosphorylation of HOXB13 by mTOR dictates its activity and oncogenic function in prostate cancer","volume":"21","author":"Chen","year":"2023","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0240","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ijc.29028","article-title":"Interruption of KLF5 acetylation converts its function from tumor suppressor to tumor promoter in prostate cancer cells","volume":"136","author":"Li","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189692_bb0245","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175949","article-title":"Interruption of KLF5 acetylation promotes PTEN-deficient prostate cancer progression by reprogramming cancer-associated fibroblasts","volume":"134","author":"Zhang","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189692_bb0250","doi-asserted-by":"crossref","first-page":"9216","DOI":"10.1158\/0008-5472.CAN-05-1040","article-title":"Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation","volume":"65","author":"Li","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0255","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/dvdy.10397","article-title":"Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis","volume":"228","author":"Shen","year":"2003","journal-title":"Dev. Dyn."},{"key":"10.1016\/j.bbcan.2026.189692_bb0260","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1158\/0008-5472.CAN-08-0578","article-title":"Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1","volume":"68","author":"Markowski","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0265","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1158\/1541-7786.MCR-14-0680","article-title":"The tumor suppressor NKX3.1 is targeted for degradation by DYRK1B kinase","volume":"13","author":"Song","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0270","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ccr.2006.03.031","article-title":"NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss","volume":"9","author":"Lei","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189692_bb0275","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.celrep.2013.06.039","article-title":"Functional activation of ATM by the prostate cancer suppressor NKX3.1","volume":"4","author":"Bowen","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2026.189692_bb0280","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1073\/pnas.1221799110","article-title":"C-Myc phosphorylation by PKC\u03b6 represses prostate tumorigenesis","volume":"110","author":"Kim","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189692_bb0285","first-page":"0990","article-title":"CDK12-mediated phosphorylation of FOXA1 promotes prostate cancer progression via the MDM2-p53 axis","volume":"8","author":"Yan","year":"2025","journal-title":"Research (Wash D C)"},{"key":"10.1016\/j.bbcan.2026.189692_bb0290","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2007.05.009","article-title":"High-resolution profiling of histone methylations in the human genome","volume":"129","author":"Barski","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189692_bb0295","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrg3173","article-title":"Histone methylation: a dynamic mark in health, disease and inheritance","volume":"13","author":"Greer","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bbcan.2026.189692_bb0300","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.11","article-title":"Writing, erasing and reading histone lysine methylations","volume":"49","author":"Hyun","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189692_bb0305","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/nar\/gkq861","article-title":"Regulation of the androgen receptor by SET9-mediated methylation","volume":"39","author":"Gaughan","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0310","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nature12451","article-title":"lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs","volume":"500","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189692_bb0315","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.13964","article-title":"ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor","volume":"5","author":"Mounir","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.bbcan.2026.189692_bb0320","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s42003-023-05709-x","article-title":"A carboxy-terminal ubiquitylation site regulates androgen receptor activity","volume":"7","author":"Arai","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0325","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/pros.21038","article-title":"Global levels of histone modifications predict prostate cancer recurrence","volume":"70","author":"Ellinger","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.bbcan.2026.189692_bb0330","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ccr.2011.09.001","article-title":"Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1","volume":"20","author":"Cai","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189692_bb0335","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114324119","article-title":"H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer","volume":"119","author":"Baratchian","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189692_bb0340","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1021\/jm500249n","article-title":"KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor","volume":"57","author":"Chu","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189692_bb0345","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature04020","article-title":"LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription","volume":"437","author":"Metzger","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189692_bb0350","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bbrc.2015.09.164","article-title":"Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo","volume":"467","author":"Wang","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189692_bb0355","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12885-017-3256-y","article-title":"Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression","volume":"17","author":"Ngollo","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2026.189692_bb0360","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1038\/s41388-021-01982-4","article-title":"Going beyond Polycomb: EZH2 functions in prostate cancer","volume":"40","author":"Park","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189692_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216815","article-title":"Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer","volume":"588","author":"Kanaoka","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189692_bb0370","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41586-025-09727-z","article-title":"NSD2 targeting reverses plasticity and drug resistance in prostate cancer","volume":"649","author":"Li","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189692_bb0375","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1038\/s41467-021-24380-6","article-title":"EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer","volume":"12","author":"Zoma","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189692_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2025.103173","article-title":"DNMT1-mediated LAMA2 inhibition induces M2 macrophage polarization during prostate cancer progression","volume":"98","author":"Li","year":"2026","journal-title":"Tissue Cell"},{"key":"10.1016\/j.bbcan.2026.189692_bb0385","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s11658-025-00818-3","article-title":"Methylation-induced silencing of AZGP1 enhances prostate cancer metastasis by stimulating tumoral glycolysis","volume":"31","author":"Li","year":"2026","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.bbcan.2026.189692_bb0390","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13238-020-00786-8","article-title":"Pioneer of prostate cancer: past, present and the future of FOXA1","volume":"12","author":"Teng","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.bbcan.2026.189692_bb0395","article-title":"SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1","volume":"120","author":"Wang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189692_bb0400","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe2261","article-title":"Posttranslational regulation of FOXA1 by Polycomb and BUB3\/USP7 deubiquitin complex in prostate cancer","volume":"7","author":"Park","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2026.189692_bb0405","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/s41588-025-02265-4","article-title":"NKX2-1 drives neuroendocrine transdifferentiation of prostate cancer via epigenetic and 3D chromatin remodeling","volume":"57","author":"Lu","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2026.189692_bb0410","doi-asserted-by":"crossref","DOI":"10.1172\/JCI187490","article-title":"PROX1 is an early driver of lineage plasticity in prostate cancer","volume":"135","author":"Duan","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189692_bb0415","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf1513","article-title":"E2F1 K117 methylation by SETD6 disrupts BRD4-E2F1 binding and modulates E2F1 chromatin binding and gene regulation in prostate cancer cells","volume":"54","author":"Ulu","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0420","article-title":"p300-mediated acetylation of KCNN4 drives enzalutamide resistance in prostate cancer","volume":"457","author":"W","year":"2026","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0425","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.3390\/ijms16034560","article-title":"Roles of ubiquitination and SUMOylation on prostate cancer: mechanisms and clinical implications","volume":"16","author":"Chen","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189692_bb0430","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1210\/me.2014-1035","article-title":"Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation","volume":"28","author":"Sutinen","year":"2014","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0435","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41580-022-00500-y","article-title":"Signalling mechanisms and cellular functions of SUMO","volume":"23","author":"Vertegaal","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0440","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1093\/emboj\/cdf406","article-title":"Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase","volume":"21","author":"Lin","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2026.189692_bb0445","article-title":"MDM2 regulates the stability of AR, AR-V7, and TM4SF3 proteins in prostate cancer","volume":"4","author":"Khatiwada","year":"2024","journal-title":"Endocr. Oncol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0450","doi-asserted-by":"crossref","first-page":"30643","DOI":"10.1074\/jbc.M403117200","article-title":"An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP)","volume":"279","author":"He","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2026.189692_bb0455","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1038\/s41467-018-07178-x","article-title":"Proteostasis by STUB1\/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189692_bb0460","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/1541-7786.MCR-17-0062","article-title":"Aurora kinase a promotes AR degradation via the E3 ligase CHIP","volume":"15","author":"Sarkar","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0465","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41585-020-0314-z","article-title":"The diverse roles of SPOP in prostate cancer and kidney cancer","volume":"17","author":"Wang","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0470","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2403331121","article-title":"USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity","volume":"121","author":"Pornour","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189692_bb0475","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2509222122","article-title":"Protein disulfide isomerases regulate androgen receptor stability and promote prostate cancer cell growth and survival","volume":"122","author":"Xie","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189692_bb0480","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.7150\/thno.109994","article-title":"Apolipoprotein E promotes primary resistance to AR-targeted therapy via inducing TRIM25-mediated AR ubiquitination and sensitizes immunotherapy in prostate cancer","volume":"15","author":"Liu","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.bbcan.2026.189692_bb0485","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccr.2009.02.021","article-title":"Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination","volume":"15","author":"Xu","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189692_bb0490","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1093\/nar\/gkw1162","article-title":"Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity","volume":"45","author":"McClurg","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0495","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ccr.2013.02.016","article-title":"The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity","volume":"23","author":"Qi","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189692_bb0500","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/onc.2017.371","article-title":"DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor","volume":"37","author":"Jing","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189692_bb0505","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2218229120","article-title":"TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer","volume":"120","author":"Singh","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189692_bb0510","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/0008-5472.CAN-22-2801","article-title":"Deregulation of SPOP in cancer","volume":"83","author":"Zhang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0515","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12943-021-01397-5","article-title":"SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions","volume":"20","author":"Jiang","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189692_bb0520","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/s41418-022-00951-y","article-title":"ERK1\/2 inhibits Cullin 3\/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression","volume":"29","author":"Fan","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2026.189692_bb0525","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13046-018-0809-0","article-title":"SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression","volume":"37","author":"Ma","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0530","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.molcel.2015.07.026","article-title":"SPOP promotes ubiquitination and degradation of the ERG Oncoprotein to suppress prostate cancer progression","volume":"59","author":"Gan","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbcan.2026.189692_bb0535","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1073\/pnas.1322198111","article-title":"Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189692_bb0540","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189692_bb0545","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2017.04.038","article-title":"MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53\/UBE4B pathway in multiple human cancer cells","volume":"401","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189692_bb0550","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1038\/onc.2017.225","article-title":"Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer","volume":"36","author":"Ashikari","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189692_bb0555","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1038\/s41388-022-02485-6","article-title":"Linear ubiquitination of PTEN impairs its function to promote prostate cancer progression","volume":"41","author":"Guo","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189692_bb0560","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/1878-0261.12844","article-title":"BAP1 suppresses prostate cancer progression by deubiquitinating and stabilizing PTEN","volume":"15","author":"Deng","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0184-0","article-title":"FAM46B inhibits cell proliferation and cell cycle progression in prostate cancer through ubiquitination of \u03b2-catenin","volume":"50","author":"Liang","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189692_bb0570","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13046-021-01843-8","article-title":"USP16 regulates castration-resistant prostate cancer cell proliferation by deubiquitinating and stablizing c-Myc","volume":"40","author":"Ge","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0575","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1038\/s41467-024-50459-x","article-title":"Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189692_bb0580","article-title":"TRIM24-mediated K27-linked ubiquitination of ULK1 alleviates energy stress-induced autophagy and promote prostate cancer growth in the context of SPOP mutation","volume":"33","author":"S","year":"2026","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2026.189692_bb0585","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41419-025-08396-0","article-title":"Fbxo2 suppresses prostate cancer progression by regulating YTHDF2 ubiquitination and degradation","volume":"17","author":"Xu","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189692_bb0590","doi-asserted-by":"crossref","DOI":"10.1172\/JCI192883","article-title":"RCC2 and CD24 cooperate to modulate prostate cancer progression through vimentin ubiquitination and \u03b2-catenin activation","volume":"135","author":"Cui","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189692_bb0595","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10142-025-01811-x","article-title":"MYC-driven TRIM27 upregulation promotes prostate cancer progression by enhancing CANX ubiquitination and activating PI3K\/AKT signaling","volume":"26","author":"Wang","year":"2026","journal-title":"Funct. Integr. Genomics"},{"key":"10.1016\/j.bbcan.2026.189692_bb0600","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41418-025-01580-x","article-title":"Induction of ferroptosis in prostate cancer by CCDC719-13 via TRIM21-mediated ubiquitination of SLC7A11","volume":"33","author":"Cheng","year":"2026","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2026.189692_bb0605","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1128\/MCB.00753-12","article-title":"Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus","volume":"32","author":"Rytinki","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0610","doi-asserted-by":"crossref","first-page":"14145","DOI":"10.1073\/pnas.97.26.14145","article-title":"Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1)","volume":"97","author":"Poukka","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189692_bb0615","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.toxlet.2014.07.003","article-title":"SUMO-specific protease 1 modulates cadmium-augmented transcriptional activity of androgen receptor (AR) by reversing AR SUMOylation","volume":"229","author":"Wu","year":"2014","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bbcan.2026.189692_bb0620","doi-asserted-by":"crossref","first-page":"9519","DOI":"10.1093\/nar\/gkae653","article-title":"Central role of SUMOylation in the regulation of chromatin interactions and transcriptional outputs of the androgen receptor in prostate cancer cells","volume":"52","author":"Launonen","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0625","article-title":"SUMOylation of EphB4 enhances its stability in prostate cancer","author":"Msn","year":"2026","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189692_bb0630","doi-asserted-by":"crossref","first-page":"929","DOI":"10.21873\/cgp.20547","article-title":"Global profiling of lysine Lactylation in prostate cancer cells","volume":"22","author":"Kim","year":"2025","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.bbcan.2026.189692_bb0635","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.cell.2024.04.002","article-title":"Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis","volume":"187","author":"Zong","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189692_bb0640","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41586-024-07620-9","article-title":"NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance","volume":"631","author":"Chen","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189692_bb0645","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi6696","article-title":"Class I histone deacetylases (HDAC1-3) are histone lysine delactylases","volume":"8","author":"Moreno-Yruela","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2026.189692_bb0650","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41421-022-00398-y","article-title":"SIRT2 functions as a histone delactylase and inhibits the proliferation and migration of neuroblastoma cells","volume":"8","author":"Zu","year":"2022","journal-title":"Cell Discov."},{"key":"10.1016\/j.bbcan.2026.189692_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110911","article-title":"Sirtuin 1\/sirtuin 3 are robust lysine delactylases and sirtuin 1-mediated delactylation regulates glycolysis","volume":"27","author":"Du","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.bbcan.2026.189692_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217070","article-title":"SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer","volume":"597","author":"Chen","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189692_bb0665","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1158\/0008-5472.CAN-25-0587","article-title":"LHX2 rewires the metabolic and epigenetic landscape to drive tumor progression in prostate cancer","volume":"85","author":"Jiang","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0670","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41420-026-03131-w","article-title":"RBM14 drives prostate cancer metastasis via stabilizing HK2 mRNA to activate glycolysis and H3K18 lactylation","volume":"12","author":"Liu","year":"2026","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bbcan.2026.189692_bb0675","article-title":"Lactate derived from cancer-associated fibroblasts promotes alternative splicing and castration resistance in prostate cancer","volume":"12","author":"Zhao","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2026.189692_bb0680","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-026-02602-z","article-title":"KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate\/hnRNPA1 lactylation\/AR-V7 axis","volume":"25","author":"Sun","year":"2026","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189692_bb0685","article-title":"Metabolic reprogramming promotes AR-V7 splicing via SRSF2 lactylation in castration-resistant prostate cancer","volume":"1","author":"Zhu","year":"2026","journal-title":"Acta Biochim. Biophys. Sin. Shanghai"},{"key":"10.1016\/j.bbcan.2026.189692_bb0690","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13046-026-03719-1","article-title":"PARP1-BCAT2 axis upregulates ABCG1 via histone lactylation to drive acquired PARP inhibitor resistance in prostate cancer","volume":"45","author":"Mei","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0695","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40364-025-00822-x","article-title":"Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer","volume":"13","author":"Ji","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0700","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-026-03141-8","article-title":"Histone lactylation modification promotes docetaxel resistance and tumor progression through CNN1-mediated autophagy and cell cycle arrest in castration-resistant prostate cancer","author":"Mao","year":"2026","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bbcan.2026.189692_bb0705","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41581-019-0129-4","article-title":"Glycosylation in health and disease","volume":"15","author":"Reily","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0710","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189692_bb0715","article-title":"O-GalNAc glycosylation activates MBL-mediated complement and coagulation cascades to drive Organotropic metastasis","volume":"12","author":"Chen","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbcan.2026.189692_bb0720","article-title":"B4GALNT4-mediated glycosylation of PDK1 activates the PI3K-AKT signaling pathway to promote prostate cancer progression","volume":"13","author":"Jiang","year":"2026","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbcan.2026.189692_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.142238","article-title":"Increased N-glycosylation of PSMA by GnT-V enhances tumor malignancy through interacting with JAK2 and the subsequent STAT3-mediated transcriptional activation in prostate cancer","volume":"307","author":"Shi","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0730","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12943-019-0979-1","article-title":"Neddylation: a novel modulator of the tumor microenvironment","volume":"18","author":"Zhou","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189692_bb0735","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3390\/cells12151973","article-title":"DCUN1D1 is an essential regulator of prostate cancer proliferation and tumour growth that acts through neddylation of cullin 1, 3, 4A and 5 and deregulation of Wnt\/catenin pathway","volume":"12","author":"Vava","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189692_bb0740","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1186\/s12967-026-08001-8","article-title":"UBE2M promotes malignant phenotypes of prostate cancer through mediating NAA10 neddylation","volume":"24","author":"Wang","year":"2026","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189692_bb0745","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbrc.2023.02.002","article-title":"Succinylation of CTBP1 mediated by KAT2A suppresses its inhibitory activity on the transcription of CDH1 to promote the progression of prostate cancer","volume":"650","author":"Zhou","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189692_bb0750","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12957-025-04068-7","article-title":"KAT3B acts as an oncogene in PCa by mediating the succinylation of c-Myc and promoting its stability","volume":"24","author":"Nie","year":"2025","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0755","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/labinvest.2008.97","article-title":"Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer","volume":"88","author":"Fiorentino","year":"2008","journal-title":"Lab. Investig."},{"key":"10.1016\/j.bbcan.2026.189692_bb0760","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240801","article-title":"LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production","volume":"15","author":"Han","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189692_bb0765","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41388-023-02718-2","article-title":"Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer","volume":"42","author":"Lin","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189692_bb0770","article-title":"ZDHHC2-dependent palmitoylation dictates ferroptosis and castration sensitivity in prostate cancer via controlling ACSL4 degradation and lipid peroxidation","volume":"13","author":"Shao","year":"2026","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbcan.2026.189692_bb0775","article-title":"Cancer cell-intrinsic cholesterol induces lipid-associated macrophage differentiation via SP1 palmitoylation to promote prostate cancer progression","volume":"13","author":"Peng","year":"2026","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbcan.2026.189692_bb0780","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41416-025-02938-1","article-title":"The long noncoding RNA lncZBTB10 facilitates AR function via S-palmitoylation to promote prostate cancer progression and abiraterone resistance","volume":"132","author":"Lin","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189692_bb0785","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/2159-8290.CD-25-0974","article-title":"Serotonin modulates lineage plasticity in neuroendocrine prostate cancer via epigenetic reprogramming","volume":"16","author":"Ji","year":"2026","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189692_bb0790","doi-asserted-by":"crossref","DOI":"10.1172\/JCI183544","article-title":"5-HT orchestrates histone serotonylation and citrullination to drive neutrophil extracellular traps and liver metastasis","volume":"135","author":"Liu","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189692_bb0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.152646","article-title":"OGT-mediated O-GlcNAcylation of OR51F2 protein aggravates the malignant phenotypes of prostate cancer cells","volume":"784","author":"Xu","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189692_bb0800","doi-asserted-by":"crossref","first-page":"31","DOI":"10.32604\/or.2026.073156","article-title":"ONX-0914 suppresses hormone-sensitive prostate cancer by promoting O-GlcNAcylation-mediated stabilization of TCF7L1","volume":"34","author":"Xian","year":"2026","journal-title":"Oncol. Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0805","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1158\/1535-7163.MCT-13-0689","article-title":"A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein","volume":"13","author":"Pop","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189692_bb0810","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1210\/me.2010-0482","article-title":"Lysine methylation and functional modulation of androgen receptor by Set9 methyltransferase","volume":"25","author":"Ko","year":"2011","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216706","article-title":"EZH2-mediated development of therapeutic resistance in cancer","volume":"586","author":"Kaur","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189692_bb0820","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189692_bb0825","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189692_bb0830","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-024-01563-4","article-title":"Wnt\/\u03b2-catenin signaling pathway in carcinogenesis and cancer therapy","volume":"17","author":"Song","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0835","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019521","article-title":"Histone modifications and cancer","volume":"8","author":"Audia","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0840","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41586-019-1347-4","article-title":"Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer","volume":"571","author":"Parolia","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189692_bb0845","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1158\/0008-5472.CAN-20-2044","article-title":"ERG-mediated coregulator complex formation maintains androgen receptor signaling in prostate cancer","volume":"80","author":"Shah","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0850","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg7112","article-title":"FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer","volume":"9","author":"Liu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2026.189692_bb0855","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1038\/onc.2016.432","article-title":"Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms","volume":"36","author":"Feng","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189692_bb0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100759","article-title":"HOXB13 facilitates hepatocellular carcinoma progression by activating AKT\/mTOR signaling pathway","volume":"28","author":"Li","year":"2023","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114661","article-title":"The role of KLF transcription factor in the regulation of cancer progression","volume":"162","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189692_bb0870","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bbcan.2026.189692_bb0880","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1158\/1078-0432.CCR-20-4391","article-title":"Abiraterone acetate induces CREB1 phosphorylation and enhances the function of the CBP-p300 complex, leading to resistance in prostate cancer cells","volume":"27","author":"Pan","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0885","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41419-021-04077-w","article-title":"KAT2A-mediated AR translocation into nucleus promotes abiraterone-resistance in castration-resistant prostate cancer","volume":"12","author":"Lu","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189692_bb0890","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41388-024-02945-1","article-title":"Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide","volume":"43","author":"Li","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189692_bb0895","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41388-023-02890-5","article-title":"UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance","volume":"43","author":"Rodriguez Tirado","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189692_bb0900","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-026-00428-1","article-title":"Targeting the RNA-binding motif protein 15 suppresses prostate cancer progression and hormone therapy resistance by promoting androgen receptor degradation","volume":"7","author":"Hu","year":"2026","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.bbcan.2026.189692_bb0905","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41419-022-05090-3","article-title":"N-glycosylation of GDF15 abolishes its inhibitory effect on EGFR in AR inhibitor-resistant prostate cancer cells","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189692_bb0910","article-title":"PDHA1-acetylation signaling suppresses cuproptosis to attenuate anti-androgen effect in prostate cancer","volume":"17","author":"R","year":"2026","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189692_bb0915","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101144","article-title":"Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer","volume":"77","author":"Lin","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bbcan.2026.189692_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2026.104188","article-title":"DNMT1-DUOXA1 axis discovers a novel methylation-ferroptosis circuit in bicalutamide-resistant prostate cancer","volume":"94","author":"Xia","year":"2026","journal-title":"Redox Biol."},{"key":"10.1016\/j.bbcan.2026.189692_bb0925","doi-asserted-by":"crossref","DOI":"10.4028\/b-XDTcg5","article-title":"Osteoblast-derived ECM1 promotes anti-androgen resistance in bone metastatic prostate cancer","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbcan.2026.189692_bb0930","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s12964-024-01897-z","article-title":"MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway","volume":"22","author":"Zheng","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bbcan.2026.189692_bb0935","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1097\/CM9.0000000000003538","article-title":"LGR5 interacts with HSP90AB1 to mediate enzalutamide resistance by activating the WNT\/\u03b2-catenin\/AR axis in prostate cancer","volume":"138","author":"Gao","year":"2025","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.bbcan.2026.189692_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101047","article-title":"PLXNA1 confers enzalutamide resistance in prostate cancer via AKT signaling pathway","volume":"57","author":"Hu","year":"2024","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2026.189692_bb0945","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.7150\/ijbs.109271","article-title":"VAV2 exists in extrachromosomal circular DNA and contributes enzalutamide resistance of prostate cancer via stabilization of AR\/ARv7","volume":"21","author":"Wang","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbcan.2026.189692_bb0950","doi-asserted-by":"crossref","first-page":"9755","DOI":"10.1038\/s41467-024-53874-2","article-title":"Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer","volume":"15","author":"Chatterjee","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189692_bb0955","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41420-026-03068-0","article-title":"SMARCA4 promotes lineage plasticity and enzalutamide resistance in prostate cancer by regulating PROX1 via H3K27 acetylation","volume":"12","author":"Wu","year":"2026","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bbcan.2026.189692_bb0960","doi-asserted-by":"crossref","first-page":"7656","DOI":"10.7150\/thno.44567","article-title":"TGF-\u03b2 causes docetaxel resistance in prostate cancer via the induction of Bcl-2 by acetylated KLF5 and protein stabilization","volume":"10","author":"Li","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bbcan.2026.189692_bb0965","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41419-024-06647-0","article-title":"ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance","volume":"15","author":"Lee","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189692_bb0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116816","article-title":"Activated Wnt\/\u03b2-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer","volume":"254","author":"Bian","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.bbcan.2026.189692_bb0975","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm.4379","article-title":"Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation","volume":"23","author":"Zhang","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189692_bb0980","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/s41467-024-45796-w","article-title":"MYC induces CDK4\/6 inhibitors resistance by promoting pRB1 degradation","volume":"15","author":"Ma","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189692_bb0985","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/0008-5472.CAN-20-2828","article-title":"HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4\/6 inhibitor resistance in cancer","volume":"81","author":"Zhou","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb0990","article-title":"Ezetimibe engineered L14-8 suppresses advanced prostate cancer by activating PLK1\/TP53-SAT1-induced ferroptosis","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbcan.2026.189692_bb0995","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.tem.2024.12.003","article-title":"Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer","volume":"36","author":"Brea","year":"2025","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2026.189692_bb1000","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.trecan.2024.01.004","article-title":"Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression","volume":"10","author":"Angappulige","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbcan.2026.189692_bb1005","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217214","article-title":"Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy","volume":"602","author":"He","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189692_bb1010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189692_bb1015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s12964-024-01805-5","article-title":"NDR1 mediates PD-L1 deubiquitination to promote prostate cancer immune escape via USP10","volume":"22","author":"Fu","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bbcan.2026.189692_bb1020","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1038\/s41418-023-01219-9","article-title":"USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1","volume":"30","author":"Kuang","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2026.189692_bb1025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41419-025-07736-4","article-title":"Mechanical signal modulates prostate cancer immune escape by USP8-mediated ubiquitination-dependent degradation of PD-L1 and MHC-1","volume":"16","author":"Ke","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189692_bb1030","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158352","article-title":"UBC9 deficiency enhances immunostimulatory macrophage activation and subsequent antitumor T cell response in prostate cancer","volume":"133","author":"Xiao","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189692_bb1035","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1158\/1078-0432.CCR-23-1441","article-title":"Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN\/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis","volume":"29","author":"Chaudagar","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb1045","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2505658122","article-title":"A PSAT1 buff of YBX1 transcriptionally sustains HLA-E-mediated evasion of NK immunity","volume":"122","author":"Zhang","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189692_bb1050","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.7150\/thno.120826","article-title":"Targeting CAMK1D-engineered nanoactivator suppresses cancer stem cell maintenance and immune evasion in enzalutamide-resistant prostate cancer","volume":"16","author":"Sun","year":"2026","journal-title":"Theranostics"},{"key":"10.1016\/j.bbcan.2026.189692_bb1055","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ccell.2024.08.018","article-title":"Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer","volume":"42","author":"Cal\u00ec","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189692_bb1060","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189692_bb1065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2017.02.030","article-title":"Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer","volume":"81","author":"Armstrong","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189692_bb1070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2017.01.024","article-title":"Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer","volume":"76","author":"Massard","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189692_bb1075","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2026.189692_bb1080","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-21-2326","article-title":"Phase Ib\/II study of enzalutamide with Samotolisib (LY3023414) or placebo in patients with metastatic castration-resistant prostate cancer","volume":"28","author":"Sweeney","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb1085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114103","article-title":"Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: results from the randomized phase II RE-AKT trial","volume":"205","author":"Rescigno","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189692_bb1090","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.20.01576","article-title":"Pan-AKT inhibitor Capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: a randomized, placebo-controlled phase II trial (ProCAID)","volume":"39","author":"Crabb","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189692_bb1095","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ymthe.2022.01.039","article-title":"Exploiting the tumor-suppressive activity of the androgen receptor by CDK4\/6 inhibition in castration-resistant prostate cancer","volume":"30","author":"Han","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2026.189692_bb1100","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1158\/1078-0432.CCR-23-3436","article-title":"A signal-finding study of Abemaciclib in heavily pretreated patients with metastatic castration-resistant prostate cancer: results from CYCLONE 1","volume":"30","author":"Agarwal","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb1105","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1158\/1078-0432.CCR-21-4302","article-title":"A phase Ib\/II study of the CDK4\/6 inhibitor Ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer","volume":"28","author":"de Kouchkovsky","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb1110","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1158\/1078-0432.CCR-21-0024","article-title":"A randomized phase II study of androgen deprivation therapy with or without Palbociclib in RB-positive metastatic hormone-sensitive prostate cancer","volume":"27","author":"Palmbos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb1115","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-20-1707","article-title":"A phase Ib\/IIa study of the Pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate Cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb1120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/1078-0432.CCR-18-1589","article-title":"Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer","volume":"25","author":"Ferrari","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb1125","article-title":"PROTACs: a novel strategy for cancer drug discovery and development","volume":"4","author":"Han","year":"2023","journal-title":"MedComm. (2020)"},{"key":"10.1016\/j.bbcan.2026.189692_bb1130","article-title":"Proteolysis-Targeting Chimera (PROTAC): current applications and future directions","volume":"6","author":"Fan","year":"2025","journal-title":"MedComm. (2020)"},{"key":"10.1016\/j.bbcan.2026.189692_bb1135","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","article-title":"Preclinical evaluation of Bavdegalutamide (ARV-110), a novel PROteolysis TArgeting chimera androgen receptor degrader","volume":"24","author":"Snyder","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189692_bb1140","article-title":"De novo design of an androgen receptor DNA binding domain-targeted peptide PROTAC for prostate cancer therapy","volume":"9","author":"Ma","year":"2022","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbcan.2026.189692_bb1145","doi-asserted-by":"crossref","first-page":"16593","DOI":"10.1021\/acs.jmedchem.5c01463","article-title":"Discovery of LYA914, an orally bioavailable PROTAC degrader targeting the DNA binding domain of the androgen receptor for the treatment of CRPC","volume":"68","author":"Lv","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189692_bb1150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104500","article-title":"Targeting androgen receptor and the variants by an orally bioavailable Proteolysis targeting chimeras compound in castration resistant prostate cancer","volume":"90","author":"Hung","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbcan.2026.189692_bb1155","article-title":"UBX-390: a novel androgen receptor degrader for therapeutic intervention in prostate cancer","volume":"11","author":"Lee","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbcan.2026.189692_bb1160","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10637-025-01533-8","article-title":"Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity","volume":"43","author":"Azad","year":"2025","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bbcan.2026.189692_bb1165","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189692_bb1170","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c01100","article-title":"Discovery of a highly potent PROTAC degrader of p300\/CBP proteins for the treatment of enzalutamide-resistant prostate cancer","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189692_bb1175","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/s41388-025-03662-z","article-title":"EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2","volume":"45","author":"Xie","year":"2026","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189692_bb1180","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189692_bb1185","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1158\/0008-5472.CAN-24-4096","article-title":"A peptide-based PROTAC degrader of BRCA2 sensitizes metastatic castration-resistant prostate cancer to PARP inhibition","volume":"85","author":"Ye","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189692_bb1190","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1016\/j.apsb.2026.03.029","article-title":"RAD51-targeting small molecule degrader sensitizes BRCA-proficient prostate cancer cells to PARP inhibitors via synthetic lethality","volume":"16","author":"Jian","year":"2026","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbcan.2026.189692_bb1195","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu0847","article-title":"Acute BRCAness induction and AR pathway blockage through CDK12\/7\/9 degradation enhances PARP inhibitor sensitivity in prostate cancer","volume":"11","author":"Gui","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2026.189692_bb1200","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-025-02444-z","article-title":"In vivo self-assembled nano-PROTAC for the dual degradation of AR and HSP90 to overcome castration-resistant prostate cancer resistance","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189692_bb1205","article-title":"Nanozyme-mediated PROTACs delivery for targeted protein degradation and ferroptosis sensitization in prostate cancer","volume":"65","author":"Wang","year":"2026","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.bbcan.2026.189692_bb1210","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.3390\/cancers13153726","article-title":"Glycosylation: rising potential for prostate cancer evaluation","volume":"13","author":"Ka\u0142u\u017ca","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189692_bb1215","doi-asserted-by":"crossref","first-page":"18974","DOI":"10.1038\/s41598-020-75526-3","article-title":"Characterisation of the main PSA glycoforms in aggressive prostate cancer","volume":"10","author":"Gratac\u00f3s-Mulleras","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189692_bb1220","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nature03672","article-title":"Global histone modification patterns predict risk of prostate cancer recurrence","volume":"435","author":"Seligson","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189692_bb1225","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41698-025-01232-w","article-title":"Plasma cell-free DNA methylation-based prognosis in metastatic castrate-resistant prostate cancer","volume":"10","author":"Wong","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.bbcan.2026.189692_bb1230","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13148-025-01932-x","article-title":"DNA methylation in normal-appearing tissue associated with prostate cancer recurrence and metastasis","volume":"17","author":"Pedersen","year":"2025","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bbcan.2026.189692_bb1235","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1038\/s41388-025-03579-7","article-title":"Aging-associated ZNF573 methylation regulates RNF19B-PIK3CA ubiquitination to promote prostate cancer","volume":"44","author":"Ge","year":"2025","journal-title":"Oncogene"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:17:38Z","timestamp":1789517858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":246,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0304419X26001642"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189692","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-translational modifications in prostate cancer: coordinated oncogenic networks and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189692"}}